Recent progress in tumour vaccine development

Expert Opinion on Investigational Drugs
I Caroline Le PooleW Martin Kast

Abstract

Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.

References

Dec 1, 2001·International Archives of Allergy and Immunology·H H SmitsE A Wierenga
Mar 23, 2002·Biochimica Et Biophysica Acta·Tsuneyasu Kaisho, Shizuo Akira
Apr 10, 2002·Cancer Immunology, Immunotherapy : CII·Andreas LundqvistPavel Pisa
Apr 16, 2002·Current Opinion in Hematology·Joseph W Fay
Apr 30, 2002·International Journal of Cancer. Journal International Du Cancer·Govindaswami RagupathiPhilip O Livingston
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Carmen ScheibenbogenUlrich Keilholz
May 16, 2002·Cancer Immunology, Immunotherapy : CII·Dorothy K SojkaMargalit B Mokyr
Jun 6, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·P A RuffiniL W Kwak
Jun 6, 2002·Journal of the National Cancer Institute·Giorgio ParmianiAndrea Anichini
Jun 12, 2002·Current Treatment Options in Oncology·Sanjiv S Agarwala
Jun 19, 2002·The Journal of Experimental Medicine·Alexis M Kalergis, Jeffrey V Ravetch
Jun 21, 2002·Current Treatment Options in Oncology·John M Timmerman
Jun 25, 2002·Proceedings of the National Academy of Sciences of the United States of America·Theresa L WhitesideEdward P Cohen
Jul 9, 2002·Clinical and Experimental Immunology·D L ShawlerR E Sobol
Jul 12, 2002·Current Gene Therapy·F Benvenuti, O R Burrone
Jul 12, 2002·Cancer Immunology, Immunotherapy : CII·Xiang-Yang WangJohn R Subjeck
Jul 12, 2002·Cancer Immunology, Immunotherapy : CII·Connie L SivinskiMichael A Hollingsworth
Jul 27, 2002·Human & Experimental Toxicology·A BadaL E Fernández
Aug 1, 2002·Journal of Peptide Science : an Official Publication of the European Peptide Society·Myriam BaratinMireille Viguier
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L Andrew DiFronzoDonald L Morton
Aug 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sacha GnjaticLloyd J Old
Aug 23, 2002·Cancer Immunology, Immunotherapy : CII·Stephen WardStephen Todryk
Aug 23, 2002·Cancer Immunology, Immunotherapy : CII·P JantscheffC F Rochlitz
Aug 28, 2002·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Ian F ParneyKenneth C Petruk
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Javier HernandezMaurizio Zanetti
Sep 14, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Mayer Fishman, John Seigne

❮ Previous
Next ❯

Citations

Mar 5, 2004·Expert Opinion on Biological Therapy·Joeli A BrinkmanW Martin Kast
Feb 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sharon H JacksonCharles E Egwuagu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.